System Guide
Back to Search Results

Search Results

Display Options
Display Options
Select Fields
Export Results to CSV Create Report 0
+ Add all results to report

Report Produced: 01/16/2026 10:03 AM

Report Question ID Question
20031175

First Course Therapy: Are radio immune labeled antibodies, such as Bexxar [Tositum--I-131] coded as immunotherapy, radiotherapy, or experimental therapy?

20031174 Multiple Primaries (Pre-2007)/Recurrence--Breast: Has SEER established a priority of medical opinions to determine the number of primaries or a time parameter establishing recurrence? When a pathologist and a physician refer to the subsequent reappearence in the same breast as both "recurrence" and "new primary"? See Description.
20031173

First Course Treatment/Hormone Therapy--Thyroid: Is hormone replacement therapy such as levothyroxine (Synthroid) for thyroid carcinoma coded as first course of treatment? See Discussion.
20031172 Hormone Therapy--Breast: Should hormonal therapy be coded as administered, when the physician states "Tamioxifen was given as a prescription?"
20031171 Reportability: Is pseudomyxoma peritonei always reportable? See Description.
20031170 Terminology, NOS/Recurrence/Multiple Primaries (Pre-2007): Is the term "residual disease" equivalent to "recurrence"? See Description.
20031169

Laterality--Head & Neck: Does the site code C098 need a laterality code? See Description.

20031167 Primary Site/Histology--CLL/SLL: How should these fields be coded when the pathological diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma is made on bone marrow biopsy only but scans show lymphadenopathy? See Description.
20031166 EOD-Regional Lymph Nodes--Breast: Are subpectoral nodes the same as interpectoral nodes and, therefore, regional for breast primaries?
20031165

Behavior Code/EOD-Extension--Colon: Are extension codes 10 [Mucosa, NOS (incl. Intramucosal, NOS)] and 11 [Lamina propria] in situ, in accordance with AJCC stage for this site?